ALK and non-small cell lung carcinoma: The second, more recent, phase III multicenter randomized adjuvant trial, ALINA (NCT03456076), is comparing alectinib to standard of care in stage IB-IIIA (TNM 7) fully resected ALK-rearranged NSCLC.